A Phase 4 interventional study of Antihemophilic factor, recombinant, manufactured protein-free and Antihemophilic factor, recombinant, manufactured protein-free in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 8 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 12th largest by enrollment, is one of 2 that started in 2006, is one of 8 in phase 4, and was the 5th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
Runhui WU · Sites in China
Ages 0–18 · Men only
By country, each count listing its studies:
antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2001; this study’s year is marked. 2 started in 2006.
This study's enrollment of 38 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 50 across the 21 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
47 studies in Hemophilia A by Takeda: none open now, 1 under way, none of them phase 3. Of 46 finished, 27 (59%) have results posted.
Among the 47 studies in Hemophilia A by Takeda, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2006, is one of 7 in phase 4, and was the 9th registered.
Takeda’s Hemophilia A studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 47 in Hemophilia A:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effect of 3 doses of ADVATE rAHF-PFM on initial recovery (% increase [IU/dL] per IU/kg infused) and major single-infusion pharmacokinetic parameters. The 3 doses are 15, 30, and 50 IU/kg. Prior to each infusion, subjects will not have received treatment with a factor VIII concentrate for at least 3 days. Blood samples will be drawn within 30 minutes pre-infusion and at 0.25, 0.5, 1, 3, 6, 9, 24, 28, 32 and 48 hours post-infusion. A washout period of at least 3 days, but no more than 30 days between the last blood draw and the next infusion will be observed. During participation, subjects will maintain their preexisting treatment regimens with ADVATE rAHF-PFM or other factor VIII concentrate.
A secondary objective is to investigate the relationship between pharmacokinetic parameters at each dose level and the levels of von Willebrand factor ristocetin cofactor activity and von Willebrand factor antigen at baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Antihemophilic factor, recombinant, manufactured protein-free
Biological: Antihemophilic factor, recombinant, manufactured protein-free
Biological: Antihemophilic factor, recombinant, manufactured protein-free
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
15 IU/kg rAHF-PFM
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
30 IU/kg rAHF-PFM
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
50 IU/kg rAHF-PFM
Initial Recovery
Percent increase in factor VIII concentration per dose from pre- to post-infusion
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion
Area Under the Curve/Dose
Area under the plasma factor VIII concentration versus time curve (AUC) estimated by linear trapezoidal method per dose.
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Terminal Half-life
Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Area Under the Curve
AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Total Area Under the Curve
Total AUC with extrapolation using the slope of the β-phase
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Total Area Under the Moment Curve
Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Weight-adjusted Clearance
Computed as weight-adjusted dose divided by total AUC
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Mean Residence Time
Computed as total AUMC divided by total AUC
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Volume of Distribution at Steady State
Computed as weight-adjusted CL \* Mean Residence Time
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Maximum Plasma Concentration
Maximal factor VIII concentration after infusion
Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)
Percentage of normal VWF:Rco activity. Normal is a lab standard consisting of a non-hemophilic population. Relationships between baseline VWF:Rco and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.
Time frame: At baseline and before each pharmacokinetic evaluation
Pre-infusion Von Willebrand Factor Antigen (VWF:Ag)
Percentage of VWF:Ag. Relationships between baseline VWF:Ag and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.
Time frame: At baseline and before each pharmacokinetic evaluation
Recruitment was conducted in the United States at 8 study sites.
| Milestone | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Started | 9 | 8 | 9 |
| Completed | 9 | 8 | 9 |
| Not completed | 0 | 0 | 0 |
| Milestone | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Started | 10 | 9 | 7 |
| Completed | 10 | 9 | 7 |
| Not completed | 0 | 0 | 0 |
| Milestone | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Started | 7 | 9 | 10 |
| Completed | 7 | 9 | 9 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Percent increase in factor VIII concentration per dose from pre- to post-infusion
| IU/dL per IU/kg | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Initial Recovery | 1.7 (0.5 to 2.7) | 1.6 (0.4 to 2.6) | 1.8 (1.2 to 2.8) |
Area under the plasma factor VIII concentration versus time curve (AUC) estimated by linear trapezoidal method per dose.
| IU*hour/dL per IU/kg | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Area Under the Curve/Dose | 21.2 (8.8 to 43.3) | 20.5 (6.5 to 42.2) | 22.3 (14.5 to 46.9) |
Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.
| hour | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Terminal Half-life | 11.3 (5.4 to 19.9) | 12.3 (6.0 to 20.0) | 11.2 (7.5 to 25.1) |
AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.
| IU*hour/dL | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Area Under the Curve | 300.1 (124.5 to 544.9) | 595.2 (167.8 to 1104.8) | 1055.8 (712.1 to 1778.3) |
Total AUC with extrapolation using the slope of the β-phase
| IU*hour/dL | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Total Area Under the Curve | 318.5 (131.8 to 648.8) | 616.3 (194.4 to 1264.8) | 1116.0 (723.3 to 2344.9) |
Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods
| IU*hour^2/dL | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Total Area Under the Moment Curve | 4760.9 (1042.9 to 16315.9) | 7115.1 (2673.6 to 28374.2) | 16464.7 (7111.4 to 77439.7) |
Computed as weight-adjusted dose divided by total AUC
| mL/kg*hour | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Weight-adjusted Clearance | 4.71 (2.34 to 11.38) | 4.88 (2.37 to 15.43) | 4.47 (2.13 to 6.91) |
Computed as total AUMC divided by total AUC
| hour | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Mean Residence Time | 14.6 (7.2 to 25.1) | 12.8 (7.5 to 24.7) | 14.7 (9.2 to 33.0) |
Computed as weight-adjusted CL \* Mean Residence Time
| dL/kg | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Volume of Distribution at Steady State | 0.7 (0.4 to 0.9) | 0.6 (0.4 to 3.4) | 0.6 (0.3 to 0.8) |
Maximal factor VIII concentration after infusion
| IU/dL | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Maximum Plasma Concentration | 26.0 (13.0 to 42.0) | 50.0 (14.0 to 79.0) | 93.0 (65.0 to 143.0) |
Percentage of normal VWF:Rco activity. Normal is a lab standard consisting of a non-hemophilic population. Relationships between baseline VWF:Rco and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.
| Percent of normal VWF:Rco activity | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco) | 83.0 (40 to 152) | 80.5 (49 to 186) | 80.5 (33 to 182) |
Percentage of VWF:Ag. Relationships between baseline VWF:Ag and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.
| U/dL | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Pre-infusion Von Willebrand Factor Antigen (VWF:Ag) | 103.0 (57 to 307) | 117.0 (63 to 309) | 109.5 (61 to 329) |
Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Population (26 Participants) | — | 0/26 (0%) | 4/26 (15.4%) |
| Event | Safety Population (26 Participants) |
|---|---|
| HeadacheNervous system disorders | 3/26 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/26 |
| Age, Categorical(Participants) | Treated Participants |
|---|---|
| <=18 years | 7 |
| Between 18 and 65 years | 19 |
| >=65 years | 0 |
| Age, Continuous(years) | Treated Participants |
|---|---|
| Mean | 23.8 ± 9.6 |
| Sex: Female, Male(Participants) | Treated Participants |
|---|---|
| Female | 0 |
| Male | 26 |
| Region of Enrollment(Participants) | Treated Participants |
|---|---|
| United States | 26 |
Ran from Feb 2006 to primary completion in Apr 2007, 13 months.
Results were first posted in Jan 2011, 3 years 9 months after primary completion.
Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human